Latest Kamada News & Updates

See the latest news and media coverage for Kamada. We track all announcements, press releases, and industry mentions in real time, all in one place.

Kamada

Global specialty plasma-derived biopharmaceutical company

kamada.com

Headquarters: Rehovot, Israel
Founded year: 1990
Company type: Public company
Number of employees: 350–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Kamada

In short: Kamada reported record financial results for the first half of 2026 and declared a $0.17 per share cash dividend to shareholders.

Company announcements

August 17 Kamada

Kamada declares $0.17 cash dividend following record first-half results

The board approved the payout reflecting strong financial performance and solid cash position to support ongoing growth strategies.

August 12 Kamada

Kamada announces planned transition of CFO Chaime Orlev

Orlev, CFO since 2017, will depart December 31, 2026, with a successor search underway.

August 12 Kamada

Kamada reports record-high first half and Q2 2026 results

Revenues reached $100.2M in H1, up 13% year-over-year, and adjusted EBITDA was $25.7M, up 14%. The company reaffirms 2026 annual guidance.

July 20 Kamada

Kamada announces a three-year $50 million plasma supply agreement

The agreement with a leading biopharmaceutical company is expected to generate revenue from Q4 2026.

Media coverage

August 13 Yahoo Finance

Should Value Investors Buy Kamada (KMDA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks....

August 7 The Globe and Mail

Kamada Delivers Record First-Half 2026 Results and Secures $50 Million Plasma Supply Deal

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities...

July 20 Markets Insider

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader...

July 13 The Globe and Mail

Kamada Sets 2026 Revenue and EBITDA Guidance Above 2025 Outlook, Affirms Current-Year Targets

Kamada ( (IL:KMDA)) has shared an announcement. On January 7, 2026, Kamada issued 2026 financial guidance projecting revenues of $200 million to $205 million and...

Never miss news about Kamada

Track Kamada and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kamada competitors & trending companies

Browse news for competitors to Kamada and other trending companies.